Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy.

Current cancer drug targets - 1 Jan 2024

Cui Saijin, Chen Tianyu, Zhao Yaning, Xiao Zhuoyun, Liu Meitong, Huang Xi, Cao Shiru, Zhou Rongmiao, Li You, Huo Xiangran, Wang Na

Abstract excerpt

BACKGROUND: Ataxia telangiectasia mutated (ATM), an apical DNA damage response gene, is a commonly mutated gene in tumors, and its mutation could strengthen tumor immunogenicity and alter the expression of PD-L1, which potentially contributes to immune checkpoint inhibitors (ICIs) therapy. METHODS: The characteristics of ATM mutation and its relationship with the ICIs-treated clinical prognosis have been analyzed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Neoplasms

Share to Prognosis

Source

Identifiers

PMID: 38804343
DOI: 10.2174/0115680096250376231025062652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy.PMID 38804343Read ↗

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune MicroenvironmentSemantic proximity Read ↗

ATM Mutations in Cancer: Therapeutic Implications.Semantic proximity Read ↗

ATM inhibition enhance antitumor immunity of CRC by activating cGAS/STING and NFκB/IRF1/NLRC5 pathwaySemantic proximity Read ↗

ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer.Semantic proximity Read ↗

Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach.Semantic proximity Read ↗

Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers.Semantic proximity Read ↗

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read ↗

Advances and prospects of biomarkers for immune checkpoint inhibitorsSemantic proximity Read ↗

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.Semantic proximity Read ↗

Ataxia-Telangiectasia Mutated (ATM) gene signaling pathways in human cancers and their therapeutic implications.Semantic proximity Read ↗

ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.Semantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.